收费全文 | 167337篇 |
免费 | 15967篇 |
国内免费 | 10444篇 |
耳鼻咽喉 | 1291篇 |
儿科学 | 2065篇 |
妇产科学 | 1919篇 |
基础医学 | 24417篇 |
口腔科学 | 2977篇 |
临床医学 | 20497篇 |
内科学 | 23620篇 |
皮肤病学 | 1749篇 |
神经病学 | 8369篇 |
特种医学 | 5851篇 |
外国民族医学 | 78篇 |
外科学 | 16171篇 |
综合类 | 27198篇 |
现状与发展 | 36篇 |
一般理论 | 16篇 |
预防医学 | 11601篇 |
眼科学 | 4025篇 |
药学 | 19176篇 |
136篇 | |
中国医学 | 9240篇 |
肿瘤学 | 13316篇 |
2024年 | 657篇 |
2023年 | 2589篇 |
2022年 | 6681篇 |
2021年 | 8451篇 |
2020年 | 6210篇 |
2019年 | 5544篇 |
2018年 | 5751篇 |
2017年 | 5342篇 |
2016年 | 5008篇 |
2015年 | 7334篇 |
2014年 | 9219篇 |
2013年 | 8752篇 |
2012年 | 12342篇 |
2011年 | 13069篇 |
2010年 | 9083篇 |
2009年 | 7304篇 |
2008年 | 9013篇 |
2007年 | 8956篇 |
2006年 | 8200篇 |
2005年 | 7647篇 |
2004年 | 5829篇 |
2003年 | 5661篇 |
2002年 | 4791篇 |
2001年 | 3980篇 |
2000年 | 3545篇 |
1999年 | 3240篇 |
1998年 | 2060篇 |
1997年 | 2143篇 |
1996年 | 1563篇 |
1995年 | 1488篇 |
1994年 | 1352篇 |
1993年 | 937篇 |
1992年 | 1165篇 |
1991年 | 1049篇 |
1990年 | 924篇 |
1989年 | 821篇 |
1988年 | 746篇 |
1987年 | 634篇 |
1986年 | 604篇 |
1985年 | 475篇 |
1984年 | 402篇 |
1983年 | 328篇 |
1982年 | 280篇 |
1981年 | 237篇 |
1980年 | 203篇 |
1979年 | 208篇 |
1978年 | 195篇 |
1977年 | 215篇 |
1976年 | 192篇 |
1974年 | 156篇 |
2. Firstly, cell viability and biochemical indicators were determined and the cell morphology was observed to confirm the cell injury and develop a cell hepatotoxicity model. Then, with the help of cell metabolomics based on UPLC-MS, the Genkwa Flos group samples were completely separated from the blank group samples in the score plots and seven upregulated as well as two down-regulated putative biomarkers in the loading plot were identified and confirmed. Besides, two signal molecules and four enzymes involved in biosynthesis pathway of lysophosphatidylcholine and the sphingosine kinase/sphingosine-1-phosphate pathway were determined to investigate the relationship between Genkwa Flos hepatotoxicity and these two classic pathways. Finally, the metabolic pathways related to specific biomarkers and two classic metabolic pathways were analyzed to explain the possible mechanism of Genkwa Flos hepatotoxicity.
3. Based on the results, lipid peroxidation and oxidative stress, phospholipase A2/lysophosphatidylcholine pathway, the disturbance of sphingosine-1-phosphate metabolic profile centered on sphingosine kinase/sphingosine-1-phosphate pathway and fatty acid metabolism might be critical participators in the progression of liver injury induced by Genkwa Flos. 相似文献
Background
Aromatic l-amino acid decarboxylase (AADC) deficiency (OMIM #608643) is a rare and severe disorder of biogenic amine synthesis caused by mutations in the DDC gene. The phenomenology of the movement disorder includes intermittent oculogyric crises and limb dystonia, generalized athetosis, and impaired voluntary movement.Objective
To identify clinical manifestations and DDC gene mutations in two Chinese mainland children who are siblings with AADC deficiency.Methods
We used targeted next-generation sequencing and quantitative polymerase chain reaction (qPCR) to reveal DDC mutations in these children.Results
Two DDC gene mutations were found: one missense mutation, c.1040G?>?A (p.Arg347Gln), is a reported mutation derived from the mother; the other mutation, a whole-exon 11 and 12 deletion, is a novel mutation derived from the father. The index patient and her brother both had poor sucking power and feeding difficulty at birth and episodes of oculogyric crises, truncal hypotonia, limb hypertonia, sleep disturbances, irritability, and motor delay. The siblings both died at 1?year and 10?months due to asphyxia and pneumonia during gaze and hypertonia episodes.Conclusion
This study identified a novel DDC gene deletion mutation in two siblings with AADC deficiency disease in the Chinese mainland population. 相似文献Methods: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge.
Results: Overall, mortality (16.2% vs. 5.3%; p?<?.01), median hospital LOS (42.0 vs. 26.0 days; p?<?.01) and median total costs ($173,144 vs. $98,982; p?<?.01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups.
Conclusion: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT. 相似文献